Fig. 2
Expression of CD44v3 in endometrial tissues and primary endometrial cells after E2 and P4 treatments (A)Immunohistochemical staining and (B) semiquantitative analysis of CD44v3 during the proliferative (n = 12) and mid-secretory phases (n = 15) in the control patients. (C) Western blot and (D) statistical analyses of CD44v3 expression in the endometrium during the proliferative and mid-secretory phases in the control group. (E and G) Western blot and (F and H) statistical analyses of CD44v3 expression in primary HESCs and HEECs with or without estrogen (E2) and progesterone (P4) treatment for 72 h. P, proliferative phase; MS, mid-secretory phase. Bar = 50 µm. *p < 0.05.